Vertex Pharma (VRTX) Posts Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Needham & Company Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:54 AM ESTNeedham & Company downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
Analyst Alan Carr commented, "Vertex reported 4Q14 financial results yesterday after market close. WW Kalydeco 4Q14 sales were $124.4M (+14% y/y). The company pre-announced net sales of approximately $120M earlier this... More
Maxim Group Downgrades Vertex (VRTX) to Hold
January 29, 2015 7:30 AM ESTMaxim Group downgraded Vertex (NASDAQ: VRTX) from Buy to Hold with a price target of $121.00 (from $148.00).
Analyst Jason Kolbert commented:
Vertex reported YE2014 non-GAAP revenue and operating expenses of $536M and $920M, respectively, and a non-GAAP loss of $511M and EPS of ($2.17). Revenue was driven largely by Kalydeco sales of $464M. Vertex enters 2015 with... More